These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3674089)

  • 1. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital.
    Woodward RS; Medoff G; Smith MD; Gray JL
    Am J Med; 1987 Nov; 83(5):817-23. PubMed ID: 3674089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems.
    Schentag JJ; Paladino JA; Birmingham MC; Zimmer G; Carr JR; Hanson SC
    J Pharm Technol; 1995; 11(5):203-10. PubMed ID: 10151512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of formulary restriction in the use of antibiotics in an Italian hospital.
    Bassetti M; Di Biagio A; Rebesco B; Amalfitano ME; Topal J; Bassetti D
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):529-34. PubMed ID: 11699621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A team approach to hospital formulary replacement.
    Lee J; Carlson JA; Chamberlain MA
    Diagn Microbiol Infect Dis; 1995; 22(1-2):239-42. PubMed ID: 7587047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approach to cost-effective antibiotic utilization.
    Venezio FR; Waitley DW
    Hosp Formul; 1988 Dec; 23 Suppl D():32-5. PubMed ID: 10312796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a selective restriction policy on antibiotic expenditure and use: an institutional model.
    Suwangool P; Moola-Or P; Waiwatana A; Sitthi-Amorn C; Israsena S; Hanvanich M
    J Med Assoc Thai; 1991 Jul; 74(7):272-5. PubMed ID: 1765742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic restriction in hospitals associated with medical schools.
    Klapp DL; Ramphal R
    Am J Hosp Pharm; 1983 Nov; 40(11):1957-60. PubMed ID: 6650526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a cephalosporin education program--a pharmacy education program.
    Sohn CA; Wolter HA; McSweeney GW
    Drug Intell Clin Pharm; 1980 Apr; 14(4):272-7. PubMed ID: 10309192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
    Huang X; Beresford E; Lodise T; Friedland HD
    Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Savings achieved through cephalosporin surveillance.
    Katz E; Schlamowitz S
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there cost reduction potential for extended half-life cephalosporins?
    Scalley RD; Stuart CC
    Drug Intell Clin Pharm; 1986 Dec; 20(12):975-80. PubMed ID: 3816548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy-laboratory interactions: a unique method to control antibiotic costs.
    Goff D; Thornton J
    Hosp Pharm; 1989 Jan; 24(1):26-9, 32. PubMed ID: 10291600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulary management as a tool to improve medication use and gain physician support.
    Lehmann DF; Guharoy R; Page N; Hirschman K; Ploutz-Snyder R; Medicis J
    Am J Health Syst Pharm; 2007 Mar; 64(5):464-6. PubMed ID: 17322158
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic exchange of cefotaxime for ceftriaxone: evaluation, implementation, and subsequent cost savings at a 300-bed community hospital.
    Rawlings RD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):235-7. PubMed ID: 7587046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.